OrthoPediatrics (KIDS) to Release Earnings on Thursday

OrthoPediatrics (NASDAQ:KIDS) is expected to be releasing its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect OrthoPediatrics to post earnings of ($0.4367) per share and revenue of $58.3390 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:30 PM ET.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%. The business had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

Shares of KIDS stock traded down $0.25 during mid-day trading on Tuesday, hitting $15.57. 79,063 shares of the stock were exchanged, compared to its average volume of 155,307. The firm has a fifty day moving average of $16.85 and a 200 day moving average of $17.32. The company has a quick ratio of 2.65, a current ratio of 5.55 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 52-week low of $14.91 and a 52-week high of $23.70. The company has a market cap of $400.07 million, a PE ratio of -9.22 and a beta of 1.16.

Analysts Set New Price Targets

KIDS has been the topic of several recent analyst reports. Canaccord Genuity Group set a $25.00 target price on shares of OrthoPediatrics in a research note on Friday. BTIG Research increased their target price on shares of OrthoPediatrics from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Tuesday, April 21st. Finally, Needham & Company LLC increased their target price on shares of OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.78.

Insider Buying and Selling

In other OrthoPediatrics news, insider Joseph W. Hauser sold 8,596 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total value of $148,281.00. Following the completion of the sale, the insider owned 194,767 shares in the company, valued at approximately $3,359,730.75. This represents a 4.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Fred Hite sold 12,993 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $224,129.25. Following the completion of the sale, the chief financial officer owned 277,477 shares of the company’s stock, valued at approximately $4,786,478.25. The trade was a 4.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 58,171 shares of company stock worth $1,003,450 in the last 90 days. Corporate insiders own 31.80% of the company’s stock.

Institutional Trading of OrthoPediatrics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. increased its holdings in shares of OrthoPediatrics by 14.5% during the 4th quarter. Invesco Ltd. now owns 39,002 shares of the company’s stock worth $693,000 after buying an additional 4,925 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of OrthoPediatrics during the 4th quarter worth approximately $188,000. Tudor Investment Corp ET AL increased its holdings in shares of OrthoPediatrics by 59.3% during the 4th quarter. Tudor Investment Corp ET AL now owns 112,996 shares of the company’s stock worth $2,007,000 after buying an additional 42,061 shares during the last quarter. Millennium Management LLC increased its holdings in shares of OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after buying an additional 452,840 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of OrthoPediatrics during the 4th quarter worth approximately $226,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.